<DOC>
	<DOCNO>NCT01447732</DOCNO>
	<brief_summary>This two-part , Phase 1 open label , multi-center , dose escalation study CEP-37250/KHK2804 monotherapy subject advance solid tumor longer respond standard therapy standard therapy available .</brief_summary>
	<brief_title>Phase 1 Study CEP-37250/KHK2804 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>The study conduct two part . In Part 1 , standard 3+3 design dose escalation phase , subject receive CEP-37250/KHK2804 , administer iv , every week . A treatment cycle consist total four dos per cycle . Part 2 study enroll subject either colon cancer pancreatic cancer receive CEP-37250/KHK2804 dose determine follow completion Part 1 . All subject receive study therapy disease progression , development unacceptable toxicity , noncompliance withdrawal consent subject , Investigator decision , maximum six cycle ( approximately six month ) . After six cycle CEP-37250/KHK2804 therapy , subject may continue receive CEP-37250/KHK2804 discussion Sponsor determination subject experience best response least stable disease ( SD ) experience unacceptable toxicity dose limit toxicity ( DLTs ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adequate hepatic , renal , hematologic function ; Life expectancy &gt; 3 month ; Part 1 2 : The subject histopathologically cytologically document , measurable , unresectable , locally advanced primary recurrent , metastatic solid tumor , locally advanced primary recurrent , metastatic pancreatic adenocarcinoma must receive least one prior treatment regimen contain gemcitabine 5FU , locally advanced primary recurrent , metastatic colon adenocarcinoma . Parts 1 2 : 1 . Malignant melanoma , Merkel cell cancer , small cell lung cancer , lymphoepithelial carcinoma , malignant mesothelioma , GIST , Hodgkin NHL , thymoma , neuroendocrine , neuronal tumor , sarcoma . This list exclude tumor may modify additional research find become available target antigen expression ; 2 . The subject receive anticancer chemotherapy , hormonal therapy , radiotherapy , immunotherapy , investigational agent within 4 week ( 6 week mitomycin C nitrosoureas ) prior first dose CEP37250/KHK2804 ; 3 . The subject receive monoclonal antibody type form disease within 4 week first dose CEP37250/KHK2804 ; 4 . Major surgery within 4 week prior first dose ; 5 . Known symptomatic brain metastasis ( screen magnetic resonance imaging ( MRI ) brain required clinical suspicion central nervous system [ CNS ] involvement past history treat brain metastasis ) . Subjects treat brain metastasis ( radiotherapy and/or surgery ) eligible : Have complete treatment brain metastasis &gt; 4 week prior schedule study treatment start date ; Are neurologically stable ; Are corticosteroids dos great physiological replacement ( e.g. , dexamethasone &lt; 1.5 mg/day ) ; Have screen MRI scan brain specifically verify evidence CNS hemorrhage active gadolinium enhance lesion ; Subjects primary brain/CNS malignancy ( e.g. , glioma , lymphoma ) exclude . Hypersensitivity reaction monoclonal antibody , therapeutic protein , allergy component CEP37250/KHK2804 finish drug reaction could control prevented subsequent infusion standard therapy antihistamine , 5HT3 antagonist , corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Monoclonal antibody ( Mab )</keyword>
	<keyword>Antibody dependent cellular cytotoxicity ( ADCC )</keyword>
	<keyword>Complement-dependent toxicity ( CDC )</keyword>
	<keyword>Non-fucosylated immunoglobulin G</keyword>
</DOC>